solution for injection
Sponsors
Celgene Corp., Biogen Idec Research Limited, Astrazeneca AB, Rhythm Pharmaceuticals Inc., Catharina Ziekenhuis Stichting
Conditions
Advanced Hepatocellular Carcinoma (HCC)Alpha (α)-thalassemiaAmyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutationEosinophilic EsophagitisImproper function of certain messenger materials in the body that control body weight and hunger in
peopleIschemic StrokeLocally Advanced Unresectable Esophageal Squamous Cell CarcinomaLocally advanced rectal cancer
Phase 2
Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke
CompletedNCT02446977
Start: 2015-03-31End: 2015-12-31Updated: 2016-10-13
A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents
RecruitingCTIS2022-502328-35-00
Start: 2023-01-30Target: 41Updated: 2025-11-14
Neo-adjuvant FOLFOXIRI and chemoradiotherapy for high risk (“ugly”) locally advanced rectal cancer.
Active, not recruitingCTIS2023-509758-74-00
Start: 2021-07-21Target: 128Updated: 2024-03-25
A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)
CompletedCTIS2023-510117-26-00
End: 2025-05-06Target: 29Updated: 2025-03-31
CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)
CompletedCTIS2024-512767-30-00
Start: 2023-09-28End: 2025-09-17Target: 23Updated: 2025-06-01
An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient treatment modality in metastatic or advanced colorectal cancer (mCRC) patients with acquired FOLFIRI resistant cancer disease
Active, not recruitingCTIS2024-518877-33-00
Start: 2022-03-17Target: 31Updated: 2024-11-19
Phase 3
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN).
Active, not recruitingCTIS2023-506413-22-00
Start: 2021-03-31Target: 48Updated: 2026-01-09
Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)
RecruitingCTIS2024-512526-28-00
Start: 2020-10-28Target: 364Updated: 2026-01-19
A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)
Active, not recruitingCTIS2023-505641-12-00
Start: 2021-07-27Target: 30Updated: 2025-08-28
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients with POMC/PCSK1, LEPR, NCOA1 (SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway
Active, not recruitingCTIS2023-507634-24-00
Start: 2022-05-20Target: 85Updated: 2025-11-28